Literature DB >> 2861454

Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate.

M Colombo, P M Mannucci, V Carnelli, G F Savidge, C Gazengel, K Schimpf.   

Abstract

In-vitro and animal studies have shown that viral agents can be removed from or inactivated in clotting factor concentrates by physical or chemical treatment. However, clinical data have as yet not substantiated the results of these studies. 13 haemophilia A patients who had not been treated previously with blood or blood products were given a dry-heated factor VIII concentrate and were tested serologically over the next 12 months. Hepatitis developed in 11 patients (84%) and was invariably of type non-A, non-B. Morbidity was not related to the lot of the therapeutic material or to the number of infusions. The incubation period was either 5 or 8-11 weeks, and only 1 patient had symptoms. Aminotransferase elevation showed both monophasic and biphasic patterns. During the follow-up period signs of the disease disappeared in 10 patients (90%). These findings contrast with the absence of non-A, non-B hepatitis in chimpanzees given the same heated concentrate. Thus, clinical studies in first-exposure haemophiliacs are essential for the true evaluation of the safety of new "treated" concentrates.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2861454     DOI: 10.1016/s0140-6736(85)90055-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  36 in total

Review 1.  Blood transfusion and hepatitis: still a threat?

Authors:  H W Reesink; C L van der Poel
Journal:  Blut       Date:  1989-01

2.  Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs.

Authors:  M G Ghany; C Leissinger; R Lagier; R Sanchez-Pescador; A S Lok
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

3.  Factor VIII concentrate for hemophilia: comparison of two heat-treated products.

Authors:  I R Walker; M K Pai; B A Blair; M A Johnston; N J Birkett; F A Ofosu; D H Naylor
Journal:  CMAJ       Date:  1987-01-15       Impact factor: 8.262

4.  Maternal and fetal screening.

Authors: 
Journal:  BMJ       Date:  1990-06-09

5.  Second malignant tumours in head and neck cancer.

Authors:  G R Ogden
Journal:  BMJ       Date:  1991-01-26

Review 6.  Factor VIII safety: plasma-derived versus recombinant products.

Authors:  Alessandro Gringeri
Journal:  Blood Transfus       Date:  2011-04-12       Impact factor: 3.443

7.  Anti HBs protection in hospital workers vaccinated against hepatitis B: policy implications of a pilot study.

Authors:  A Yassi; M McGill; S Jeanson
Journal:  Br J Ind Med       Date:  1990-09

8.  Safety trial of heated factor VIII concentrate (8Y).

Authors:  K J Pasi; F G Hill
Journal:  Arch Dis Child       Date:  1989-10       Impact factor: 3.791

9.  Keratin profiles of normal and malignant oral mucosa using exfoliative cytology.

Authors:  G R Ogden; S McQueen; D M Chisholm; E B Lane
Journal:  J Clin Pathol       Date:  1993-04       Impact factor: 3.411

10.  Excitability of the motor cortex to magnetic stimulation in patients with cerebellar lesions.

Authors:  V Di Lazzaro; D Restuccia; M Molinari; M G Leggio; R Nardone; D Fogli; P Tonali
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-01       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.